Results 121 to 130 of about 138,235 (308)

Sustained delivery and molecular targeting of a therapeutic monoclonal antibody to metastases in the central nervous system of mice. [PDF]

open access: yes, 2019
Approximately 15-40% of all cancers develop metastases in the central nervous system (CNS), yet few therapeutic options exist to treat them. Cancer therapies based on monoclonal antibodies are widely successful, yet have limited efficacy against CNS ...
Chen, Irvin SY   +17 more
core  

Why Pediatric CAR‐T Therapies Still Lag Behind: Insights from Six Treatments Centrally Approved in Europe

open access: yes
Clinical Pharmacology &Therapeutics, EarlyView.
Lisa Hanquet   +2 more
wiley   +1 more source

Isolated Pleural Effusion as Presentation of a Large B‐Cell Lymphoma: A Case Report and Diagnostic Considerations

open access: yesJournal of Clinical Laboratory Analysis, EarlyView.
A 79‐year‐old man presented with massive pleural effusion in which cytological examination revealed lymphoma cells without evidence of a solid tumor mass. Negative EBV in situ hybridization and negative HHV8 and HIV testing, combined with flow cytometric immunophenotyping and molecular findings, supported a diagnosis of fluid overload–associated large ...
Van Vlierberghe Magalie   +5 more
wiley   +1 more source

Complete remission with ibrutinib after allogeneic stem cell transplant for central nervous system relapse of mantle cell lymphoma: A case report and literature review

open access: yesClinical Case Reports, 2019
Central nervous system (CNS)‐relapsed mantle cell lymphoma (MCL) is a rare, aggressive non‐Hodgkin lymphoma without a standard treatment. Ibrutinib has shown promising results for inducing remission in other non‐Hodgkin lymphomas and may be considered as
Jessica D. Rich   +5 more
doaj   +1 more source

Assessment of Potential Sources of Variability on the Analytical Performance of a Circulating Tumor DNA Minimal Residual Disease Test for B‐Cell Lymphomas

open access: yesJournal of Clinical Laboratory Analysis, EarlyView.
Laboratory tests must exhibit robustness to common sources of test variability, particularly for tests with the potential to inform treatment decisions. This study presents data that shows that a phased variant enrichment and detection sequencing (PhasED‐Seq)‐based circulating tumor DNA minimal residual disease (ctDNA‐MRD) test is robust, with results ...
Nina Klimova   +7 more
wiley   +1 more source

Can Burkitt's Lymphoma and Hodgkin's Lymphoma occur in siblings simultaneously?

open access: yesThe Turkish Journal of Pediatrics, 2015
Familial clustering of Hodgkin lymphoma (HL) and increased risk of developing disease among the siblings has been reported earlier. Usually familial lymphoma in sibling pairs occurs in the pairs of either non-Hodgkin lymphoma or HL.
Meriç Kaymak Cihan   +5 more
doaj  

Hodgkin lymphoma of the ampulla of Vater: A rare cause of obstructive jaundice in children

open access: yesJPGN Reports, EarlyView.
Abstract Hodgkin lymphoma (HL) has a wide spectrum of presentation. Most cases affect lymph nodes (nodal), while extranodal involvement is rare. Whereas the gastrointestinal tract is enriched with lymphoid tissues, the ampulla of Vater is not rich in lymphoid tissue. Involvement of the ampulla of Vater with HL has rarely been reported in adults and has
Sultana Alshammari   +12 more
wiley   +1 more source

Diagnostic criteria and new therapeutic options for patients diagnosed with non-Hodgkin lymphoma

open access: yesArchivo Médico de Camagüey, 2019
Background: malignant haemopathies increase their incidence and proliferation within the population, among them the lymphoproliferative syndrome occupies an important place, it is a group of disorders of clonal origin, which affects the lymphoid cells ...
Yaimé Moreno-Laguard   +5 more
doaj  

Categorization of Reasons for Hospitalizations in Patients With Cutaneous T‐Cell Lymphoma

open access: yesJEADV Clinical Practice, EarlyView.
ABSTRACT Background Cutaneous T‐cell lymphomas (CTCL) can significantly impact patients' quality of life as well as impose a substantial healthcare burden due to their complex management and risk of hospitalization. Objectives This study aimed to identify factors associated with hospital admissions among patients with CTCL and to characterize the ...
Geetha Gowda   +6 more
wiley   +1 more source

Assessment of Treatment Response in Patients With Scleromyxedema by the Double Modified Rodnan Skin Score

open access: yesJEADV Clinical Practice, EarlyView.
ABSTRACT Background Scleromyxedema (SMX) is a cutaneous mucinosis characterised by an abnormal accumulation of mucin in the skin and limited treatment options. Assessment of therapy response during treatment is challenging. Objectives Patients with SMX receiving high‐dose intravenous IVIg therapy were included to assess validity of the double modified ...
Julia K. Winkler, Alexander H. Enk
wiley   +1 more source

Home - About - Disclaimer - Privacy